{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:59:38Z","timestamp":1788242378868,"version":"build-2803163510"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ceva Sant\u00e9 Animal"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose transport 2 inhibitors (SGLT2i) decrease morbidity and mortality in human patients with heart failure through a variety of proposed mechanisms, including natriuresis and glucosuria. The effects of SGLT2i on urine sodium (uNa) and urine glucose (uGlu) concentrations in dogs with heart disease have not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Administration of the SGLT2i dapagliflozin to dogs with heart disease will be well-tolerated and increase uNa and uGlu concentrations. Laboratory results and biomarker assays will provide insight into potential mechanisms of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Ten client-owned dogs with heart disease with or without congestive heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective multicenter open-label uncontrolled study. Blood and urine biochemistry and oxidative and inflammatory biomarkers were evaluated at baseline and 5-7\u00a0days after 0.45-1\u00a0mg\/kg\/day PO dapagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A treatment effect was observed for uGlu (baseline, 14\u00a0mg\/dL; IQR, 2-19\u00a0mg\/dL; treatment effect +3102\u00a0mg\/dL; IQR, 2390-4387\u00a0mg\/dL; P\u00a0=\u00a0.002) but not for uNa (baseline, 75\u00a0mmol\/L; IQR, 28-129\u00a0mmol\/L; treatment effect, \u221241\u00a0mmol\/L; IQR, \u221296-21\u00a0mmol\/L; P\u00a0=\u00a0.12). Serum total thiol concentration increased (baseline, 145\u00a0\u03bcmol\/L; SD, 32\u00a0\u03bcmol\/L; treatment effect, +7\u00a0\u03bcmol\/L; SD, 9\u00a0\u03bcmol\/L; P\u00a0=\u00a0.04), suggesting an antioxidative effect. Serious adverse effects, including hypoglycemia or ketoacidosis, were not observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Short-term PO dapagliflozin was well-tolerated and associated with glucosuria but not natriuresis. Clinical benefit of SGLT2i in dogs with heart disease might include non-natriuretic mechanisms, such as anti-inflammatory, antioxidative, or metabolic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag036","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:18:00Z","timestamp":1773091080000},"source":"Crossref","is-referenced-by-count":1,"title":["Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart disease"],"prefix":"10.1093","volume":"40","author":[{"given":"Laura K","family":"Massey","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Advanced Medicine School of Veterinary Medicine, University of Pennsylvania , 3900 Delancy St, Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, Lloyd Veterinary Medical Center College of Veterinary Medicine, Iowa State University , 1809 S. Riverside Dr, Ames, IA 50011 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra V","family":"Crooks","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Advanced Medicine School of Veterinary Medicine, University of Pennsylvania , 3900 Delancy St, Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Guillot","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale , 8 Rue de Logrono, Libourne 33500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ceron","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Campus Mare Nostrum, University of Murcia , Murcia 30100 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rubio","sequence":"additional","affiliation":[{"name":"Interdisciplinary Laboratory of Clinical Analysis of the University of Murcia (Interlab-UMU), Campus Mare Nostrum, University of Murcia , Murcia 30100 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Convey","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Advanced Medicine School of Veterinary Medicine, University of Pennsylvania , 3900 Delancy St, Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Tropf","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, Lloyd Veterinary Medical Center College of Veterinary Medicine, Iowa State University , 1809 S. Riverside Dr, Ames, IA 50011 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jyun","family":"Ciou","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, Lloyd Veterinary Medical Center College of Veterinary Medicine, Iowa State University , 1809 S. Riverside Dr, Ames, IA 50011 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P","family":"Mochel","sequence":"additional","affiliation":[{"name":"Precision One Health Initiative College of Veterinary Medicine, The University of Georgia , 501 D. W. Brooks Drive, Athens, GA, 30602 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Advanced Medicine School of Veterinary Medicine, University of Pennsylvania , 3900 Delancy St, Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026042110464798100_ref1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042110464798100_ref2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026042110464798100_ref3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042110464798100_ref4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042110464798100_ref5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2026042110464798100_ref6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026042110464798100_ref7","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.3390\/ijms25137057","article-title":"The renoprotective mechanisms of sodium-glucose cotransporter-2 inhibitors (SGLT2i)\u2014a narrative review","volume":"25","author":"Iordan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026042110464798100_ref8","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm12082824","article-title":"Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease","volume":"12","author":"Rastogi","year":"2023","journal-title":"J Clin Med"},{"key":"2026042110464798100_ref9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2460\/javma.24.03.0174","article-title":"Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the sensation study","volume":"262","author":"Behrend","year":"2024","journal-title":"J Am Vet Med Assoc"},{"key":"2026042110464798100_ref10","first-page":"52","article-title":"Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus","volume":"86","author":"Benedict","year":"2022","journal-title":"Can J Vet Res"},{"key":"2026042110464798100_ref11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/jvim.17053","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs","volume":"38","author":"Box","year":"2024","journal-title":"J Vet Intern Med"},{"key":"2026042110464798100_ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvp.13472","article-title":"Sodium glucose transporter 2 inhibitors: will these drugs benefit non-diabetic veterinary patients with cardiac and kidney diseases?","volume":"48","author":"Elliott","year":"2025","journal-title":"J Vet Pharmacol Ther"},{"key":"2026042110464798100_ref13","doi-asserted-by":"publisher","first-page":"e1454","DOI":"10.1002\/vms3.1454","article-title":"Effect of the sodium-glucose cotransporter-2 inhibitor, dwp16001, as an add-on therapy to insulin for diabetic dogs: a pilot study","volume":"10","author":"An","year":"2024","journal-title":"Vet Med Sci"},{"key":"2026042110464798100_ref14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1111\/jvim.15562","article-title":"Echocardiographic quantitation of left heart size and function in 122 healthy dogs: a prospective study proposing reference intervals and assessing repeatability","volume":"33","author":"Visser","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026042110464798100_ref15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"Acvim consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026042110464798100_ref16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1939-165X.2008.00010.x","article-title":"Fractional excretion tests: a critical review of methods and applications in domestic animals","volume":"37","author":"Lefebvre","year":"2008","journal-title":"Vet Clin Pathol"},{"key":"2026042110464798100_ref17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/ckj\/sfw034","article-title":"The utility and accuracy of four equations in predicting sodium levels in dysnatremic patients","volume":"9","author":"Hanna","year":"2016","journal-title":"Clin Kidney J"},{"key":"2026042110464798100_ref18","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2460\/javma.2005.226.1864","article-title":"Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease","volume":"226","author":"Freeman","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"2026042110464798100_ref19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1177\/1040638716664939","article-title":"Validation of three automated assays for total antioxidant capacity determination in canine serum samples","volume":"28","author":"Rubio","year":"2016","journal-title":"J Vet Diagn Invest"},{"key":"2026042110464798100_ref20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12917-016-0792-7","article-title":"Spectrophotometric assays for total antioxidant capacity (tac) in dog serum: an update","volume":"12","author":"Rubio","year":"2016","journal-title":"BMC Vet Res"},{"key":"2026042110464798100_ref21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12917-020-02650-7","article-title":"Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure","volume":"16","author":"Rubio","year":"2020","journal-title":"BMC Vet Res"},{"key":"2026042110464798100_ref22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12917-023-03586-4","article-title":"Changes in biomarkers of redox status in serum and saliva of dogs with hypothyroidism","volume":"19","author":"Arostegui","year":"2023","journal-title":"BMC Vet Res"},{"key":"2026042110464798100_ref23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1177\/1091581813505331","article-title":"Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor","volume":"32","author":"Tirmenstein","year":"2013","journal-title":"Int J Toxicol"},{"key":"2026042110464798100_ref24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12917-022-03324-2","article-title":"Evaluation of safety and anti-obesity effects of dwp16001 in naturally obese dogs","volume":"18","author":"Rhee","year":"2022","journal-title":"BMC Vet Res"},{"key":"2026042110464798100_ref25","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"2026042110464798100_ref26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jvim.16730","article-title":"Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus","volume":"37","author":"Hadd","year":"2023","journal-title":"J Vet Intern Med"},{"key":"2026042110464798100_ref27","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jvim.17124","article-title":"Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats","volume":"38","author":"Niessen","year":"2024","journal-title":"J Vet Intern Med"},{"key":"2026042110464798100_ref28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026042110464798100_ref29","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026042110464798100_ref30","doi-asserted-by":"publisher","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026042110464798100_ref31","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1681\/ASN.2016111178","article-title":"Compensatory distal reabsorption drives diuretic resistance in human heart failure","volume":"28","author":"Rao","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026042110464798100_ref32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026042110464798100_ref33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-023-01946-w","article-title":"Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure","volume":"22","author":"Packer","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026042110464798100_ref34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2026042110464798100_ref35","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2026042110464798100_ref36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2026042110464798100_ref37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","article-title":"Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress","volume":"117","author":"Packer","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026042110464798100_ref38","doi-asserted-by":"publisher","first-page":"e016270","DOI":"10.1161\/JAHA.120.016270","article-title":"Molecular, cellular, and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure","volume":"9","author":"Packer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026042110464798100_ref39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/vcp.12278","article-title":"Correlation of serum cardiac troponin i and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease","volume":"44","author":"Polizopoulou","year":"2015","journal-title":"Vet Clin Pathol"},{"key":"2026042110464798100_ref40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2460\/ajvr.78.4.447","article-title":"Plasma coenzyme q10 concentration, antioxidant status, and serum n-terminal pro-brain natriuretic peptide concentration in dogs with various cardiovascular diseases and the effect of cardiac treatment on measured variables","volume":"78","author":"Svete","year":"2017","journal-title":"Am J Vet Res"},{"key":"2026042110464798100_ref41","doi-asserted-by":"publisher","first-page":"131703","DOI":"10.1016\/j.molstruc.2021.131703","article-title":"The dynamics of hemoglobin-haptoglobin complexes. Relevance for oxidative stress","volume":"1250","author":"Carrascoza","year":"2022","journal-title":"J Molec Struct"},{"key":"2026042110464798100_ref42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jacc.2012.09.063","article-title":"Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin","volume":"61","author":"Cahill","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026042110464798100_ref43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1161\/ATVBAHA.107.153965","article-title":"Vitamin e supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial","volume":"28","author":"Milman","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026042110464798100_ref44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.phrs.2016.06.027","article-title":"Serum free thiols in chronic heart failure","volume":"111","author":"Koning","year":"2016","journal-title":"Pharmacol Res"},{"key":"2026042110464798100_ref45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/13813455.2020.1773505","article-title":"Prognostic value of thiol\/disulfide homeostasis in symptomatic patients with heart failure","volume":"127","author":"Caliskan","year":"2021","journal-title":"Arch Physiol Biochem"},{"key":"2026042110464798100_ref46","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"2026042110464798100_ref47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026042110464798100_ref48","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction: the emperor-preserved trial","volume":"12","author":"Doehner","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026042110464798100_ref49","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026042110464798100_ref50","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the emperor-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"2026042110464798100_ref51","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/dom.13991","article-title":"Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: a subanalysis of EMPA-REG OUTCOME","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026042110464798100_ref52","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026042110464798100_ref53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/metabo14050264","article-title":"Ketoacidosis and SGLT2 inhibitors: a narrative review","volume":"14","author":"Morace","year":"2024","journal-title":"Metabolites"},{"key":"2026042110464798100_ref54","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"2026042110464798100_ref55","doi-asserted-by":"publisher","first-page":"165739","DOI":"10.1016\/j.bbadis.2020.165739","article-title":"Cardiac ketone body metabolism","volume":"1866","author":"Abdul Kadir","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2026042110464798100_ref56","doi-asserted-by":"publisher","first-page":"120404","DOI":"10.1016\/j.atherosclerosis.2025.120404","article-title":"Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction","volume":"407","author":"Mylonas","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026042110464798100_ref57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaccao.2024.12.004","article-title":"SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics","volume":"7","author":"Medina-Hernandez","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026042110464798100_ref58","doi-asserted-by":"publisher","first-page":"e015298","DOI":"10.1161\/CIRCIMAGING.123.015298","article-title":"Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction","volume":"16","author":"Santos-Gallego","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026042110464798100_ref59","doi-asserted-by":"publisher","first-page":"e011980","DOI":"10.1161\/CIRCHEARTFAILURE.124.011980","article-title":"Metabolic effects of the SGLT2 inhibitor dapagliflozin in heart failure across the spectrum of ejection fraction","volume":"17","author":"Selvaraj","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026042110464798100_ref60","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"key":"2026042110464798100_ref61","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jcp.30621","article-title":"Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease","volume":"237","author":"Ravindran","year":"2022","journal-title":"J Cell Physiol"},{"key":"2026042110464798100_ref62","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042110464798100_ref63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/a-2347-9824","article-title":"Genito urinary infection and urinary tract infection in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors: evidence from a systematic literature review of landmark randomized clinical trial","volume":"74","author":"Arshad","year":"2024","journal-title":"Drug Res (Stuttg)"},{"key":"2026042110464798100_ref64","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026042110464798100_ref65","doi-asserted-by":"publisher","first-page":"743807","DOI":"10.3389\/fendo.2021.743807","article-title":"Comprehensive analysis of adverse events associated with SGLT2is: a meta-analysis involving nine large randomized trials","volume":"12","author":"Qiu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/2\/aalag036\/67281707\/aalag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/2\/aalag036\/67281707\/aalag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:46:52Z","timestamp":1776782812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag036\/8512406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag036","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"aalag036"}}